[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Ratnarathorn M, Newman J: Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report. Dermatol Online J; 2008;14(8):6
Hazardous Substances Data Bank. COLCHICINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report.
  • Sneddon-Wilkinson disease or subcorneal pustular dermatosis (SPD) is a rare, benign inflammatory skin disorder of unknown etiology.
  • Herein, we report the first case of SPD in association with marginal zone lymphoma.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / complications. Skin Diseases, Vesiculobullous / diagnosis
  • [MeSH-minor] Acitretin / adverse effects. Acitretin / therapeutic use. Anemia / etiology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colchicine / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Female. Fluocinonide / therapeutic use. Humans. Middle Aged. Neutropenia / chemically induced. Prednisone / therapeutic use. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. ACITRETIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061566.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 2W4A77YPAN / Fluocinonide; 4F4X42SYQ6 / Rituximab; LCH760E9T7 / Acitretin; SML2Y3J35T / Colchicine; VB0R961HZT / Prednisone
  •  go-up   go-down


2. Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M: Marginal zone-related neoplasms of splenic and nodal origin. Haematologica; 2003 Jan;88(1):80-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone-related neoplasms of splenic and nodal origin.
  • BACKGROUND: The marginal zone is an anatomically distinct B-cell compartment of lymphoid tissue with an abundant antigenic influx.
  • Among marginal zone-derived lymphomas the WHO classification listed, in addition to extranodal marginal zone B-cell lymphoma of MALT type, two other marginal zone B-cell neoplasms: splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) and nodal marginal zone B-cell lymphoma (+/- monocytoid B cells).
  • Treatment options are heterogeneous, including a watch-and-wait policy, surgery with or without chemotherapy, purine analogs, and interferon.
  • STATE OF THE ART: Splenic and nodal marginal zone lymphomas are typical low-grade lymphomas with an indolent course.
  • The role played by hepatitis C virus (HCV) in marginal zone lymphomas is not fully elucidated, but there is demonstration that eradication of HCV infection in splenic lymphoma with villous lymphocytes causes regression of the lymphoma.
  • The optimal treatment has not yet been identified.
  • The optimal therapeutic approach and the role of new treatments need to be assessed in prospective clinical trials.
  • [MeSH-major] Lymphoma, B-Cell / pathology
  • [MeSH-minor] Humans. Lymph Nodes / pathology. Prognosis. Spleen / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12551831.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 95
  •  go-up   go-down


3. Donfrid M, Apostolski S, Suvajdzić N, Janković G, Cemerikić-Martinović V, Atkinson HD, Colovic M: Monocytoid B cell lymphoma associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Acta Haematol; 2001;106(3):130-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monocytoid B cell lymphoma associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside.
  • Monocytoid B cell lymphoma (MBCL) is an immunologically and morphologically well-defined low-grade lymphoma with a predilection for lymph nodes of the parotid region.
  • The diagnosis of stage IV MBCL with nodular bone marrow infiltration, Sjögren's syndrome and sensorimotor polyneuropathy was made in October 1996.
  • After six cycles of chemotherapy (ChlVPP protocol), all the patient's haematological parameters normalized accompanied by an improvement in neurological signs.
  • The improvement of the polyneuropathy after chemotherapy indicates that the autoimmune anti-MAG and anti-SGPG antibodies resulted from the neoplastic lymphoid proliferation.
  • [MeSH-major] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Globosides / immunology. Lymphoma, B-Cell / immunology. Lymphoma, Non-Hodgkin / immunology. Myelin-Associated Glycoprotein / immunology. Neoplasm Proteins / immunology. Paraproteins / immunology
  • [MeSH-minor] Autoantibodies / immunology. Autoimmune Diseases / complications. Humans. Immunoglobulin M / immunology. Immunoglobulin kappa-Chains / immunology. Lymph Nodes / pathology. Male. Middle Aged. Parotitis / etiology. Purpura / etiology. Sensation Disorders / etiology. Sjogren's Syndrome / complications. Spleen / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11713380.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Globosides; 0 / Immunoglobulin M; 0 / Immunoglobulin kappa-Chains; 0 / Myelin-Associated Glycoprotein; 0 / Neoplasm Proteins; 0 / Paraproteins; 0 / sulfate-3-glucuronyl paragloboside
  •  go-up   go-down


Advertisement
4. Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, Harada M, Kikuchi M: A "floral" variant of nodal marginal zone lymphoma. Hum Pathol; 2005 Feb;36(2):202-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A "floral" variant of nodal marginal zone lymphoma.
  • We describe 6 cases of a specific variant of nodal marginal zone lymphoma with "floral" lymph follicles in patients ranging in age from 18 to 66 years.
  • Histologically, all lesions had a distinctive morphology, with proliferation of medium-sized atypical lymphoid cells in the marginal zone, hyperplastic lymph follicles with enlarged germinal centers, and a thickened mantle zone.
  • On immunohistochemical staining, the atypical lymphoid cells showed a B-cell phenotype (CD20 +), IgM positivity in 2 of 5 cases, and negativity for CD5, CD10, CD23, CD43, bcl-6, and IgD.
  • Five patients did not receive adjuvant chemotherapy and had no recurrences.
  • The patient with systemic lymphadenopathy received chemotherapy and had a complete response without relapse.
  • This variant should be differentiated from the usual nodal marginal zone lymphoma because of its specific clinical and pathological features.
  • [MeSH-major] Germinal Center / pathology. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Female. Humans. Hyperplasia. Immunoglobulin Heavy Chains / genetics. Immunoglobulin M / analysis. Immunoglobulin Variable Region / drug effects. Immunohistochemistry. Lymphatic Diseases. Male. Middle Aged. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754298.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin M; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


5. Baraboutis IG, Marinos L, Lekakis LJ, Papastamopoulos V, Georgiou O, Tsagalou EP, Rondogianni P, Apostolidis J, Papadaki T, Skoutelis AT: Long-term complete regression of nodal marginal zone lymphoma transformed into diffuse large B-cell lymphoma with highly active antiretroviral therapy alone in human immunodeficiency virus infection. Am J Med Sci; 2009 Dec;338(6):517-21
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term complete regression of nodal marginal zone lymphoma transformed into diffuse large B-cell lymphoma with highly active antiretroviral therapy alone in human immunodeficiency virus infection.
  • Since the introduction of combination antiretroviral therapy (cART), there has been a decrease in the incidence of non-Hodgkin lymphoma among the HIV-infected population and also significantly improved survival rates.
  • We describe a remarkable case of a HIV-infected patient whose large B-cell lymphoma, most likely arising by transformation of a nodal marginal zone lymphoma, completely regressed with the use of cART alone.
  • He remained disease-free for almost 3 years and he finally died from presumed flare up of his lymphoma.
  • There are very few cases of spontaneous regression of lymphomas with cART alone in the HIV population.
  • This is an extreme example of the significance of cART in improving survival in HIV-non-Hodgkin lymphoma and changing the face of the HIV epidemic in general.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell, Marginal Zone / complications. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010159.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


6. Ferreri AJ, Zucca E: Marginal-zone lymphoma. Crit Rev Oncol Hematol; 2007 Sep;63(3):245-56
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal-zone lymphoma.
  • The term marginal-zone lymphoma (MZL) encompasses three closely related lymphoma subtypes, namely the "low-grade B-cell lymphoma of MALT type" currently named MALT lymphoma, the "nodal marginal-zone B-cell lymphoma" and a provisional entity in the REAL classification named "primary splenic MZL with or without villous lymphocytes".
  • These entities display different characteristics, with evident clinical and biological variations according to the organ where the lymphoma arises.
  • Marginal-zone B-cells are functionally heterogeneous and may differ with respect to the pattern of somatic hypermutation in their Ig variable genes.
  • Sequence and mutation analysis of the rearranged Ig heavy chain variable genes and that somatic mutations pattern indicate that MZL may arise from different subsets of marginal-zone B-cells.
  • Pathogenesis of these groups of lymphomas is correlated to chronic infections, like Helicobacter pylori, hepatitis C virus, Campylobacter jejuni, Chlamydia psittaci and Borrelia burgdorferi.
  • Several therapeutic strategies against these malignancies exist.
  • Surgical resection, radiotherapy and alkylating agent-based chemotherapy constitute standard approaches, while antimicrobial therapies, anti-CD20 therapy and new forms of immunotherapy constitute interesting experimental approaches.
  • However, prospective trials on these malignancies are rare and universally accepted therapeutic guidelines do not exist.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Prognosis. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583528.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 114
  •  go-up   go-down


7. Haas RL, Poortmans P, de Jong D, Verheij M, van der Hulst M, de Boer JP, Bartelink H: Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer; 2005 Aug;41(12):1724-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients.
  • In this work, we have studied the response rates and duration of response after low-dose (4 Gy) involved field radiotherapy (LD-IF-RT) in relapsed or chemotherapy refractory indolent and aggressive lymphoma patients.
  • 71 patients (177 symptomatic sites) received LD-IF-RT consisting of 39 males and 32 females with a median age of 69 years (range 43-93).
  • Patients included were those with small lymphocytic lymphoma/chronic lymphocytic leukaemia (n=23), marginal zone lymphoma, nodal type (n=18), mantle cell lymphoma (n=17), and diffuse large B-cell lymphoma (n=13).
  • A median of two prior chemotherapy regimens (range 0-10) preceded LD-IF-RT.
  • Median time since diagnosis was 31 months (range 1-216 months).
  • Time to (local) progression was calculated according to the Kaplan-Meier method.
  • The median time to progression (TP) was 12 months and the median time to local progression (TLP) was 22 months.
  • None of the factors studied (age, sex, lymphoma subtype, radiotherapy regimen, number of prior regimens or time since diagnosis, number of positive sites or largest lymphoma diameter) were found to relate to response.
  • At time of death 70% of patients were without in-field progression after LD-IF-RT.
  • It appears that LD-IF-RT is a valuable asset in the management of relapsed disease in both indolent and aggressive lymphoma and should be considered to palliate symptoms in patients with recurrent and/or chemotherapy refractory disease.
  • [MeSH-major] Lymphoma / radiotherapy. Palliative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Disease-Free Survival. Drug Resistance, Neoplasm. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy / adverse effects. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039113.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Oertel J, Oertel B, Dörken B: Detection of small numbers of cells characteristic for haematological disorders in peripheral blood (the deep diff). Clin Lab Haematol; 2002 Apr;24(2):73-80
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of small numbers of cells characteristic for haematological disorders in peripheral blood (the deep diff).
  • We studied cytocentrifuge preparations of peripheral blood mononuclear leucocytes in haematological patients with nondiagnostic white cell differential counts.
  • This approach (the 'deep diff') enabled the detection of small numbers of diagnostically significant cells in a majority of patients.
  • We observed centrocytes in seven patients with follicular lymphoma, mantle cells in five patients with mantle cell lymphoma and marginal zone cells in five patients with nodal marginal zone lymphoma.
  • We detected small percentages of lymphoma cells in cytospins of mononuclear leucocytes in 12 patients with large B-cell lymphoma, Burkitt's lymphoma and anaplastic large-cell lymphoma.
  • The deep diff was nondiagnostic in 5/6 patients with hairy cell leukaemia and in 9/10 patients with Waldenström's macroglobulinaemia and small lymphocytic lymphoma.
  • Increased counts of leukaemic cells were found in 12/13 patients with acute leukaemia with < 3% blasts in the conventional white cell differential.
  • Decreased blasts were found in five patients with aplastic anaemia and in nine patients with bone marrow aplasia after intensive chemotherapy.
  • Increased plasma cell counts were observed in 13/14 patients with advanced plasma cell myeloma.
  • We conclude that the 'deep diff', augmented by immunocytochemistry, may be useful in the diagnosis of haematological disorders.
  • [MeSH-major] Blood Cell Count. Hematologic Diseases / blood
  • [MeSH-minor] Anemia / blood. Anemia, Refractory, with Excess of Blasts / blood. Centrifugation. Coloring Agents. Eosine Yellowish-(YS). Humans. Leukemia / blood. Lymphoma, Non-Hodgkin / blood. Methylene Blue. Neoplastic Cells, Circulating. Retrospective Studies. Staining and Labeling / methods. Waldenstrom Macroglobulinemia / blood

  • MedlinePlus Health Information. consumer health - Blood Count Tests.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11985551.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


9. Arcaini L, Bruno R: Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. Curr Clin Pharmacol; 2010 May;5(2):74-81
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.
  • The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas has been demonstrated in epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan and southern parts of United States.
  • Marginal zone lymphomas are the histotypes that are most frequently associated with HCV infection.
  • The WHO classification comprises extranodal marginal zone B-cell lymphoma of MALT type, splenic marginal zone B-cell lymphoma and nodal marginal zone B-cell lymphoma.
  • Recently, antiviral treatment has been proved to be effective in the treatment of HCV-positive patients with indolent lymphoma, prevalently of marginal zone origin.
  • This is the strongest evidence of a causative link between HCV and lymphomas.
  • Aim of this review is to illustrate the relationship between HCV infection and marginal zone lymphomas and to systematically summarize the data from the therapeutic studies where antiviral treatment with alpha-interferon with or without ribavirin was employed in patients with marginal zone lymphomas.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy
  • [MeSH-minor] Drug Therapy, Combination. Humans. Interferon-alpha / therapeutic use. Ribavirin / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156155.001).
  • [ISSN] 2212-3938
  • [Journal-full-title] Current clinical pharmacology
  • [ISO-abbreviation] Curr Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin
  • [Number-of-references] 87
  •  go-up   go-down


10. Koh LP, Lim LC, Thng CH: Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol; 2000 Aug;17(3):225-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.
  • A patient with advanced and chemotherapy-refractory nodal marginal zone B-cell lymphoma was given a course of chimeric CD 20 monoclonal antibody Rituximab.
  • This case demonstrates the therapeutic efficacy and feasibility of retreatment with Rituximab for relapsed or refractory low grade lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Disease Progression. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):89-91 [9760161.001]
  • [Cites] Blood. 1982 Sep;60(3):693-7 [7104493.001]
  • [Cites] Ann Intern Med. 1972 Feb;76(2):227-34 [5066691.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1962-3 [10561242.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1573-82 [7687667.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):128-38 [10319381.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1851-7 [10561225.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • (PMID = 10962535.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


11. Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon PA, Thieblemont C, Coiffier B, Salles G, Berger F: A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology; 2006 Jan;48(2):162-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases.
  • AIMS: To report the clinicopathological findings of 21 cases of primary nodal marginal zone B-cell lymphoma (NMZL).
  • NMZL is a recently characterized lymphoma and few series have been published.
  • METHODS AND RESULTS: The clinical data were characteristic of a disseminated disease at presentation: presence of peripheral and abdominal lymph nodes, bone marrow involvement (62%), disease stage III and IV (76%), elevated lactate dehydrogenase (LDH) (48%).
  • Relapses were frequent but the majority of patients receiving chemotherapy had a good initial response.
  • Morphological features were heterogeneous and there were some differences compared with other marginal zone B-cell lymphomas (MZL).
  • Pure monocytoid B-cell lymphomas were rare (10%) but a minor component of monocytoid B cell was observed more frequently (23%).
  • [MeSH-major] Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / analysis. Bone Marrow / pathology. DNA-Binding Proteins / analysis. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunohistochemistry. Karyotyping. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Proto-Oncogene Proteins c-bcl-2 / analysis. Survival Analysis. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405665.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


12. Koenigsmann M, Knauf W, Herold M, Pasold R, Müller G, Eschenburg H, Kahl C, Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A: Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). Leuk Lymphoma; 2004 Sep;45(9):1821-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
  • The therapy of patients with relapsed or refractory indolent lymphoma relies on the development of new drug combinations.
  • The drugs bendamustine and fludarabine have cytotoxic activity as monotherapy in indolent lymphoma and show synergism in vitro.
  • In this study, we combined both drugs in a multicenter clinical phase I/II trial to evaluate their toxicity and efficacy.
  • Bendamustine was given at 30 or 40 mg/m2/d (dose levels 1 and 2), fludarabine at 30 mg/m2/d, each drug on days 1 to 3.
  • A total of 29 patients with relapsed or refractory indolent lymphoma were included in the study.
  • Fourteen patients had follicular lymphoma, 11 patients mantle cell lymphoma, 2 patients lymphoplasmocytic and 2 patients nodal marginal zone lymphoma.
  • All patients were in stages III or IV of their disease and had received prior chemotherapy with or without additional radio- or immunotherapy.
  • Analysis of 19 evaluable patients treated at dose level 1 reveiled hematotoxicity CTC grade III in 47% and grade IV in 26%.
  • Nine of 9 patients with mantle cell lymphoma responded to therapy.
  • Eight of 15 responders relapsed after a median follow-up time of 14 months (range 2-43).
  • Dose level 1 with 30 mg/m2/d of both drugs on days 1 to 3 was defined as the recommended dose.
  • [MeSH-major] Hematology. Lymphoma / drug therapy. Lymphoma / pathology. Medical Oncology. Nitrogen Mustard Compounds / therapeutic use. Societies, Medical. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Adult. Aged. Bendamustine Hydrochloride. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Taylor and Francis Ltd
  • (PMID = 15223642.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


13. Krasić D, Radović P, Burić N, Cosić A, Katić V: [MALT lymphoma of the parotid salivary gland]. Vojnosanit Pregl; 2007 Jan;64(1):53-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MALT lymphoma of the parotid salivary gland].
  • BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma was described for the first time in 1983 by Isaacson and Wright.
  • It was classified into extranodal non-Hodkin's lymphomas of B-cell lymphocytes of the marginal zone of reactive lymphe follicles.
  • It is characterized by both hyperplasia and colonization of plasmocytic, centrocytoid and monocytoid cells, by the infiltration of interfollicular and parafollicular parts of interstitium, as well as by the invasion of clusters of neoplastic lymphoid cells of the glandular epithelium, forming the pathognomic lymphoepithelial MALT limphoma lesions.
  • CASE REPORT: In this paper we presented the two female patients, 59 and 75 years of age, with MALT lymphomas, associated with Miculicz's and Sjögren's syndromes.
  • After the subtotal parotidectomy, using conservation of nerve facialis, the tissue blocks were fixed in 10% formaldehyde.
  • The paraffine sections were stained by routine histochemical and an immunohistochemical method by using monoclonal antibodies for both B-cell and T-cell lymphomas, due to the verification of lymphoepithelial lesions.
  • The MALT lymphoma diagnosis was based on the histological criteria and confirmed by an immunohistochemical method.
  • After the surgical therapy accompanied by chemotherapy, the patients were controlled at regular intervals, and residual MALT lymphoma did not appear.
  • CONCLUSION: MALT lymphoma is a rare tumor of the salivary glands, with the most frequent localization in the parotide gland.
  • The diagnosis was made pathohistologically and confirmed immunohistochemically.
  • The surgical therapy was accompained by adjuvant chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone. Parotid Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304725.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


14. Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, Kwon JM, Lee HR, Ko YH, Oh SJ, Park KW, Kim HJ, Kwon HC, Nam E, Kim JH, Park YH, Lee SS, Kim HY, Park K: Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol; 2006 Nov;85(11):781-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.
  • Nodal marginal zone B-cell lymphoma (NMZL) is a relatively uncommon type of lymphoma.
  • Because of the rarity, the natural history and the optimal treatment modality have not been well defined.
  • Therefore, we performed a retrospective analysis of the clinical features and treatment outcomes of NMZL.
  • Most patients were categorized as low or low-intermediate risk group by international prognostic index (IPI) (77.1%).
  • Majority (94.4%) of the patients with localized disease achieved complete remission (CR) after the initial treatment.
  • Of the seven patients with disseminated disease, who were treated with anthracycline-based chemotherapy, four patients achieved CR.
  • Of the seven patients who received nonanthracycline-based chemotherapy, no patient achieved CR.
  • The significant predictive factors for PFS were performance status, advanced stage, and follicular lymphoma IPI (FLIPI) in this study.
  • This clinical feature is similar to FL rather than to MZL-MALT type.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Marrow Neoplasms. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847665.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents
  •  go-up   go-down


15. Bertoni F, Zucca E: State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol; 2005 Sep 10;23(26):6415-20
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State-of-the-art therapeutics: marginal-zone lymphoma.
  • Marginal-zone lymphomas comprise the mucosa-associated lymphoid tissue (MALT) type (extranodal marginal-zone lymphoma [EMZL]), the nodal marginal zone B-cell lymphoma (NMZL) and the splenic MZL (SMZL).
  • These data have determined unique approach among all other lymphoma subtypes: the possibility of treating a subset of patients with antibiotics alone as first line of treatment.
  • Indeed, there is compelling evidence that histologic regressions can be achieved in most gastric MALT lymphomas by eradicating Helicobacter pylori infection.
  • However, molecular follow-up studies showed the persistence of the malignant clone in half of the cases in histologic remission after antibiotic treatment and transient, either histologic or molecular, relapses have been reported, too.
  • Hence, a careful long-term follow-up is mandatory after antibiotic treatment.
  • Radiotherapy, chemotherapy, anti-CD20 monoclonal antibodies are effective alternative therapies.
  • Differently from EMZL, both SMLZ and NMZL often present with disseminated disease at diagnosis.
  • The therapeutic approach comprises splenectomy, for SMZL, and chemotherapy, but with no consensus about the best treatment.
  • This review addresses the current knowledge on the clinical features and therapeutic approaches for the individual MZLs.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Helicobacter Infections / drug therapy. Immunotherapy / methods. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Helicobacter pylori / drug effects. Helicobacter pylori / isolation & purification. Humans. Male. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Severity of Illness Index. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155028.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 79
  •  go-up   go-down


16. Kumarappan CT, Mandal SC: Antitumor activity of polyphenolic extract of Ichnocarpus frutescens. Exp Oncol; 2007 Jun;29(2):94-101
Hazardous Substances Data Bank. VITAMIN E .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PPE cytotoxicity was determined in vitro in U-937 monocytoid leukemia and K-562 erythroleukemia cell lines.
  • RESULTS: Results of in vivo study showed a significant decrease in tumor volume, viable tumor cell count and a significant increase of life span in the PPE treated group compared to untreated one: the life span of PPE treated animals increased by 53.41% (50 mg PPE/kg) and 73.95% (100 mg PPE/kg).
  • PPE (5, 10 and 20 microg/mL) effectively inhibits in vitro proliferation of U-937 and K-562 cell lines.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Flavonoids / chemistry. Phenols / chemistry. Plant Extracts / therapeutic use
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Body Weight / drug effects. Carcinoma, Ehrlich Tumor / drug therapy. Cell Count. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Female. Free Radical Scavengers / pharmacology. Humans. Inhibitory Concentration 50. K562 Cells. Leukemia, Erythroblastic, Acute / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Mice. Neoplasm Transplantation. Nitric Oxide / chemistry. Nitric Oxide / metabolism. Plant Leaves / chemistry. Polyphenols. Solvents / chemistry. Superoxides / metabolism. Survival Rate. Toxicity Tests, Acute. Transplantation, Homologous. Tumor Burden / drug effects. U937 Cells. alpha-Tocopherol / pharmacology

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704739.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Flavonoids; 0 / Free Radical Scavengers; 0 / Phenols; 0 / Plant Extracts; 0 / Polyphenols; 0 / Solvents; 11062-77-4 / Superoxides; 31C4KY9ESH / Nitric Oxide; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


17. Honma Y: A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors. Leuk Lymphoma; 2001 Sep-Oct;42(5):953-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors.
  • The adenosine deaminase inhibitor 2'-deoxycoformycin (dCF) significantly inhibits the proliferation of leukemia and lymphoma cells in the presence of either 2'-deoxyadenosine (dAdo) or its analog adenine arabinoside (araA).
  • The concentration of dCF required to induce apoptosis of monocytoid leukemia cells is much lower than that required for myeloid, erythroid, or lymphoma cells. dATP effectively induces caspase-3 activation in cytosol from monocytoid cells, but not in that from non-monocytoid cells, suggesting that dATP-dependent caspase-3 activation is involved in the preferential induction of apoptosis in monocytoid leukemia cells.
  • Athymic nude mice inoculated with human monocytoid leukemia U937 cells show significantly prolonged survival following combined treatment with dCF and araA.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Adenosine Deaminase Inhibitors. Animals. Apoptosis / drug effects. Cell Differentiation / drug effects. Deoxyadenosines / therapeutic use. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697650.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adenosine Deaminase Inhibitors; 0 / Deoxyadenosines; 0 / Enzyme Inhibitors
  • [Number-of-references] 75
  •  go-up   go-down


18. Qiu L, Unger PD, Dillon RW, Strauchen JA: Low-grade mucosa-associated lymphoid tissue lymphoma involving the kidney: report of 3 cases and review of the literature. Arch Pathol Lab Med; 2006 Jan;130(1):86-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade mucosa-associated lymphoid tissue lymphoma involving the kidney: report of 3 cases and review of the literature.
  • Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue involving the kidney is rare.
  • The second case was a 53-year-old man with a history of sarcoidosis who was found, in the course of evaluation of sarcoidosis, to have a right renal mass.
  • The third case occurred in a 72-year-old man who had a history of periorbital mucosa-associated lymphoid tissue lymphoma and had been treated with surgery and radiation 1 year prior to this presentation.
  • Histologically, all 3 patients showed infiltrate of uniform small-to-medium-sized lymphocytes with irregular nuclear contours and abundant cytoplasm resembling centrocytes or monocytoid lymphoid cells.
  • The first patient received chemotherapy without complications.
  • The third patient developed a pulmonary embolism following nephrectomy, and further follow-up is not available.
  • [MeSH-major] Kidney Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Back Pain / complications. Back Pain / pathology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary. Nephrectomy. Sarcoidosis / complications. Sarcoidosis / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390244.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Li BZ, Yu CJ, Xu JJ, Lu HF, Shi DR: [Clinicopathologic characteristics and chromosomal abnormalities in salivary mucosa associated lymphoid tissue lymphomas]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Aug;44(8):651-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics and chromosomal abnormalities in salivary mucosa associated lymphoid tissue lymphomas].
  • OBJECTIVE: To study the morphological and genetic characteristics in salivary gland marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) lymphomas.
  • METHODS: Twenty-eight cases of MALT lymphomas of salivary gland were collected from Department of Pathology, Cancer Hospital of Fudan University.
  • Twenty-two (78.6%) showed prominent monocytoid B cells and more often formed broad halos around epithelial islands.
  • Except surgical resection, patients did not get systematic radio-or chemotherapy.
  • Eight to fifteen months after operation, 8 cases found recurred nodules on the original resected sites or cervical lymph nodes, but did not get repeated biopsy.
  • All follow-up time was from 23 to 54 months.
  • CONCLUSIONS: Most salivary MALT lymphomas are arising from parotid glands.
  • The final diagnosis depends on the pathological findings, the number and distribution of monocytoid B cells and clusters of plasmacytoid cells are hints for diagnosis of salivary MALT lymphomas, invasion of blood vessels or nerve also help for malignant diagnosis. t(11;18) and trisomy 18 may be the main chromosomal abnormalities in salivary gland MALT lymphomas, but with low morbidity.
  • This genetic characteristic may connect with the low malignancy and slow progression in biological behavior.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961773.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Pamuk GE, Demir M, Orüm H, Turgut B, Ozyilmaz F, Tekgündüz E: Secondary amyloidosis causing nephrotic syndrome in a patient with non-Hodgkin's lymphoma: quite a rare diagnosis. Clin Lab Haematol; 2006 Aug;28(4):259-61
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary amyloidosis causing nephrotic syndrome in a patient with non-Hodgkin's lymphoma: quite a rare diagnosis.
  • Amyloidosis cases during the course of non-Hodgkin's lymphoma (NHL) are usually of AL-type, only one NHL patient with secondary amyloidosis has been reported.
  • Our 79-year-old male patient visited us with multiple lymphadenopathies, and he was diagnosed with nodal marginal zone B-cell lymphoma.
  • After four cycles of combined chemotherapy; his urea, creatinine levels started to increase and he developed nephrotic-range proteinuria.
  • The patient has been under hemodialysis for 10 months and his lymphoma is still in partial remission.
  • We presented this case because it is the second NHL patient who developed secondary amyloidosis during his disease course.
  • [MeSH-major] Amyloidosis / etiology. Lymphoma, B-Cell / complications. Nephrotic Syndrome / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898966.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Zhang YN, Zheng YY, Zhou XG, Zhang SH, Jin Y, Xie JL, Chen SY, Shi Y, Wu LH: [Clinicopathologic study of splenic marginal zone B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Apr;38(4):243-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of splenic marginal zone B-cell lymphoma].
  • OBJECTIVE: To study the clinicopathologic features, diagnosis and differential diagnosis of splenic marginal zone B-cell lymphoma (SMZL).
  • Post-operative fludarabine-based chemotherapy was given to 3 patients, two of them achieved complete remission and 1 case died during the course of chemotherapy.
  • The average survival time was 21.5 months (range: 6 to 60 months).
  • Six of them exhibited the classic biphasic appearance with central aggregates of small B cells rimmed by a peripheral zone of atypical monocytoid B cells.
  • The remaining 2 cases had a monomorphous appearance, consisting mainly of atypical monocytoid B cells.
  • The proliferation index, as highlighted by Ki-67 immunostaining, was low (< 15%).
  • CONCLUSIONS: SMZL is an indolent B-cell non-Hodgkin lymphoma.
  • The main modality of treatment is splenectomy.
  • Adjuvant fludarabine-based chemotherapy helps to achieve complete remission.
  • In general, the prognosis of this lymphoma type is good.
  • The lymphoma cells predominantly grow in micronodular pattern, with atypical monocytoid B cells rimming around the small B cells, which aggregates in the center.
  • The differential diagnosis includes other small B-cell lymphomas and lymphoid hyperplasia of spleen.
  • [MeSH-major] Antigens, CD20 / metabolism. Lymphoma, B-Cell, Marginal Zone / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Immunophenotyping. Ki-67 Antigen / metabolism. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Spleen / pathology. Splenectomy. Survival Rate

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575895.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down






Advertisement